Specialty Pharmacy

Medicare-insured patients with heart disease had the greatest access to PCSK9 inhibitors.

Acalabrutinib (Calquence) found to improve overall response rate among patients with mantle cell lymphoma.

Ozanimod may slow multiple sclerosis progression more than first-line therapy.

Bevacizumab (Avastin) may improve progression-free survival among treatment-naïve patients with ovarian cancer.

A byproduct of cholesterol metabolism may fuel the spread of solid tumors.

Top news of the day from across the healthcare landscape.

Research questions whether reducing sodium intake could reduce the risk of developing multiple sclerosis.

Rinku Patel, PharmD, RPh, CEO and founder of KloudScript, discusses the struggle with high-cost specialty medications and the alternatives for providing specialty pharmacy care.

Pharmacy wholesaler stocks dropped significantly due to concerns over retail giant Amazon entering the pharmacy space.

New discovery about EGFR signaling may prevent cancer cells from spreading.

Top news of the day from across the healthcare landscape.

Fingolimod shows 82% efficacy reducing the annualized multiple sclerosis relapse rate.

Rina Shah, PharmD, Vice President, Pharmacy Operations and Specialty Pharmacy, Walgreens, speaks to the merits of partnering with continuing education and advocacy organizations.

Employers provide coverage for 56% of the insured population, which carries significant weight with pharmacy benefit managers.

Top news of the week from Specialty Pharmacy Times.

Combination therapy found to reverse multiple sclerosis in mice models.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the healthcare landscape.

Once-daily HIV treatment found to be highly effective and well-tolerated in treating antiretroviral-naïve HIV-1 patients.

The emergence of biosimilars will reduce spending on biologics by 3% through 2027.

Varubi indicated for use in combination with other antiemetic agents to treat delayed chemotherapy-induced nausea and vomiting in adults.

Genome analysis points to potential new treatments for patients with chordoma.

Novel drug causes apoptosis in leukemia cells, while leaving healthy blood cells unscathed.

Top news of the day from across the healthcare landscape.

Gocovri is the only FDA-approved therapy for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy.

How pharmacists can reduce polypharmacy and potentially inappropriate prescribing among the aging HIV population.

This paper examines the use and implications of direct and indirect remuneration (DIR) fees and potential strategies to overcome the challenges that accompany DIR fees.

Grant Knowles, PharmD, vice president, Business Development, Ardon Health, discusses the potential impact biosimilars will have in health care.